FDA Warns of Next-Day Impairment with Sleep Aid Lunesta (eszopiclone)

As seen in the Consultant Connection June - July 2014 Issue
On May 15 the Food and Drug Administration (FDA) warned that the insomnia drug eszopiclone can cause next-day impairment of driving and other activities that require alertness. As a result, the recommended starting dose has been lowered to 1 mg at bedtime. Health care professionals should follow the new dosing recommendations when starting patients on eszopiclone. Patients should continue taking their prescribed dose of eszopiclone and contact their health care professionals to ask about the most appropriate dose for them.

Back to Articles